Novo Nordisk's Balancing Act: A Paediatric Breakthrough Meets a Deepening Pipeline Wound

Novo Nordisk halts two more Ziltivekimab trials, while STEP-YOUNG data shows semaglutide reduces obesity in children, ahead of investor day.

The Danish pharmaceutical giant arrives at a pivotal moment with two very different stories to tell — one that strengthens its core franchise, another that erodes confidence in its ability to diversify.

Novo Nordisk confirmed on Tuesday that it has terminated two more Phase 3 trials of its cardiovascular candidate Ziltivekimab, with HERMES and ATHENA both halted after an independent committee concluded the likelihood of positive outcomes was too low. The decision follows the failure of the ZEUS programme in July, leaving only the ARTEMIS study in post-heart-attack patients still running, with data not expected until the first half of 2027.

The setback lands at an awkward time. According to Jyllands-Posten, the company is set to host analysts and investors in London in roughly two weeks, where chief executive Mike Doustdar will be tasked with rebuilding the growth narrative. The cardiology retreat sharpens the stakes for that appearance considerably.

A Rare Bright Spot in the Pipeline

Just a day before the trial terminations were confirmed, the company reported encouraging results from the STEP-YOUNG Phase 3 study. Among children aged six to under twelve with severe obesity, weekly semaglutide combined with diet and exercise led to 40.4 percent of participants no longer qualifying as obese after 68 weeks, compared with zero percent in the placebo group. More than 85 percent of those enrolled had class II or III severe obesity at baseline.

The data marks the first study of its kind in this young age group — Eli Lilly has yet to publish comparable figures — and opens a potential new patient segment for the company's flagship drug. Yet the commercial timeline warrants caution: paediatric approvals typically move slowly, and the revenue impact is unlikely to be felt in the near term.

The Corvidia Bet That Soured

Ziltivekimab's collapse carries particular sting given its provenance. The IL-6 inhibitor arrived via the $725 million acquisition of Corvidia in 2020, a deal that positioned the drug as a cornerstone of Novo Nordisk's ambitions beyond diabetes and obesity. Two failed studies in quick succession suggest that capital has largely been written off.

The broader industry context offers some consolation. Novartis simultaneously disclosed that its cardiovascular candidate Pelacarsen missed its primary endpoint in an advanced trial, hinting that heart-disease drug development has become a sector-wide challenge rather than a company-specific failure.

Still, Deutsche Bank's decision to downgrade the stock to "Sell" in late August now looks prescient rather than premature.

What the Market Is Saying

The share price has been drifting sideways with a downward bias. At the time of the announcements, the stock traded at €39.83, roughly 27 percent below its 52-week high of €54.86 reached in January. The relative strength index of 46.8 points to a market that has absorbed the mixed news without panic — neither oversold nor overbought territory.

Barclays has trimmed its price target to DKK 300 from DKK 310 while maintaining an "Equal Weight" rating, signalling that at least one major house sees no imminent reversal. The stock now sits just below its 200-day moving average of €40.15, a technical marker that suggests the medium-term trend remains under pressure.

The Core Question for Investors

The bull case rests on semaglutide's durability. An independent analysis of 23 Phase 3 trials encompassing more than 16,500 diabetes patients found that semaglutide at comparable doses achieves weight-loss effects similar to Lilly's Tirzepatide — evidence that dosing, not molecular superiority, drives outcomes. The STEP-YOUNG results reinforce that the drug's clinical utility extends beyond its current indications.

The bear case, however, is equally compelling. Three failed cardiovascular studies within months reveal a pattern: outside diabetes and obesity, Novo Nordisk has yet to demonstrate meaningful clinical depth. And while the equivalence data shows semaglutide can compete, it also undermines any claim of a clear competitive edge.

Adding to the caution, Citi has flagged Brazilian import data for polypeptide hormone-based medications — a proxy for weight-loss drug demand — falling 22 percent in August compared with July. The figure is regional, but it hints that the Wegovy growth story may face elasticity constraints and biosimilar competition sooner than expected.

What London Must Deliver

The upcoming investor day has become the focal point for a stock caught between scientific achievement and commercial uncertainty. Doustdar needs to articulate how the company will fill the gap left by Ziltivekimab's demise while convincing investors that semaglutide's expansion across new indications and patient populations can sustain the growth trajectory.

Until then, the equity remains a test of conviction: whether the strength of the core franchise outweighs a pipeline that has repeatedly stumbled beyond its established territory. The paediatric data suggests the science is intact. Whether that translates into renewed investor confidence is a question the London meeting may — or may not — answer.